Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma

The effectiveness of chemotherapy in hepatocellular carcinoma (HCC) is restricted by chemo-resistance and systemic side effects. To improve the efficacy and safety of chemotherapeutics in HCC management, scientists have attempted to deliver these drugs to malignant tissues using targeted carriers as...

Full description

Saved in:

Bibliographic Details
Published in:	Seminars in cancer biology Vol. 69; pp. 91 - 99
Main Authors:	Elnaggar, Muhammed H., Abushouk, Abdelrahman I., Hassan, Ahmed H.E., Lamloum, Hadeer M., Benmelouka, Amira, Moatamed, Shurouk A., Abd-Elmegeed, Hossam, Attia, Somia, Samir, Aya, Amr, Nouran, Johar, Dina, Zaky, Samy
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-02-2021
Subjects:	Active targeting Animals Antineoplastic Agents - administration & dosage Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Chemotherapy Drug Delivery Systems Hepatocellular carcinoma Humans Liver Neoplasms - drug therapy Liver Neoplasms - pathology Nanomedicine Nanoparticles Nanoparticles - administration & dosage Nanoparticles - chemistry TFR NP HDL-R M6P HCC IGF Hepatocellular carcinoma EGFR mAb Nanoparticles Chemotherapy PLGA LDL-R GPC3 SSTR HA Active targeting IgA-R Nanomedicine ASGP-R CD44
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The effectiveness of chemotherapy in hepatocellular carcinoma (HCC) is restricted by chemo-resistance and systemic side effects. To improve the efficacy and safety of chemotherapeutics in HCC management, scientists have attempted to deliver these drugs to malignant tissues using targeted carriers as nanoparticles (NPs). Among the three types of NPs targeting (active, passive, and stimuli-responsive), active targeting is the most commonly investigated in HCC treatment. Despite the observed promising results so far, clinical research on nanomedicine targeting for HCC treatment still faces many challenges.These include batch-to-batch physicochemical properties' variations, limiting large scale production and insufficient data on human and environmental toxicities. This review summarized the characteristics of different nanocarriers, ligands, targeted receptors on HCC cells and provided recommendations to overcome the challenges, facing this novel line of treatment for HCC.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1044-579X 1096-3650
DOI:	10.1016/j.semcancer.2019.08.016